

Supplementary Methods

Assay design and analysis

This study was implemented as part of a research project involving genetic causes of Monogenic Diabetes.

Formerly, *HNFI1A*, one of the most frequent MODY genes, was analyzed by Sanger sequencing. No pathogenic variant was identified in the coding region.

Due to negative result, next-generation sequencing (NGS) was performed. We designed a customized NGS panel including **51 nuclear genes** [**7 MODY genes** (*HNFI1A*, *HNFI1A*, *KLF11*, *CEL*, *PAX4*, *BLK*, *APPL1*), **7 genes** related to **MODY and Neonatal Diabetes** (*GCK*, *PDX1*, *HNFI1B*, *NEUROD1*, *INS*, *ABCC8*, *KCNJ11*), **17 Neonatal Diabetes genes** (*PTF1A*, *NEUROG3*, *RFX6*, *ZFP57*, *GLIS3*, *IER3IP1*, *GATA6*, *GATA4*, *EIF2AK3*, *SLC19A2*, *SLC2A2*, *CP*, *PLAGL1*, *HYMAI*, *NKX2-2*, *MNX1*, *PAX6*), **3 Monogenic Autoimmune Diabetes genes** (*FOXP3*, *AIRE*, *STAT3*), **2 Wolfram Syndrome genes** (*WFS1*, *CISD2*), **1 gene** associated with **Insulin Resistance Syndromes** (*INSR*), **11 Lipodystrophy genes** (*AGPAT2*, *BSCL2*, *CAVI*, *PTRF*, *LMNA*, *PLIN1*, *ZMPSTE24*, *AKT2*, *CIDEC*, *TBC1D4*, *PPARG*), **3 Familial Hyperinsulinemic Hypoglycemia genes** (*HADH*, *GLUD1*, and *SLC16A1*)], in addition to **mitochondrial genome**. Target region comprised all exons, intron-exon boundaries, and promoter regions. After sequencing, bioinformatics analysis of the generated genomic data was implemented using in-house pipelines (based on BWA-MEM, FreeBayes, and ANNOVAR), comprising steps such as sequence alignment, calling variants and genomic annotation. Investigation of sequence variants included: 1- filtering called variants; 2- visualization by Integrative Genomics Viewer software (IGV); and 3- analysis of copy number variation (CNV) using Copy Number Targeted Resequencing Analysis (CONTRA). The analysis was performed considering all genes possibly associated with the patient's phenotype.